expresspharmaJanuary 08, 2021
Tag: Healthcare , venture capital , Biopharma
In December 2020, the healthcare industry reported 103 deals worth $55.3 billion as compared to the last 12-month average (December 2019 to November 2020) of 83 deals worth $13.5 billion.
AstraZeneca to acquire Alexion Pharmaceuticals, a biopharma company, for $39 billion or $175 per share was the big-ticket deal which contributed 70.5 per cent of the total deal value in December 2020. Other top deals during the period were EQT IX Fund to acquire Recipharm AB, a contract development and manufacturing organisation, for approximately $2.1 billion; Les Laboratoires Servier SAS to acquire commercial, clinical and research-stage oncology portfolio of Agios Pharmaceuticals, a biopharma company, for up to $2 billion and Gilead Sciences to acquire MYR GmbH for $1.7 billion.
VC investments value decreased in December 2020
The healthcare industry reported 112 venture capital (VC) deals worth $3.8 billion in December 2020, compared to the last 12-month average (December 2019 to November 2020) of 121 deals worth $3 billion.
Tempus Labs, a technology company specialised in advancing precision medicine through the collection and analysis of molecular and clinical data, raising $200 million in series G-2 financing round to expand its operations and establish its work in other disease areas, including infectious diseases, depression, and cardiology; Nuance Biotech, raising $181 million in series D round of financing to support its ongoing research and development of its existing products and business development of potential new assets, and Cullinan Oncology, raising $131.2 million in series C round of financing are the major VC deals reported in December 2020.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: